Industry News

Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• J&J and Smith+Nephew $34 Billion Mega-Merger Talks Collapse Over Leadership Dispute: Reported by Orthopedics This Week, proposed negotiations to combine their orthopaedics units into a 34 billion dollar entity collapsed over chief executive appointment disputes, directing J&J toward a standalone public spin-off for DePuy Synthes.
• Twenty-Year KAT Randomized Controlled Trial Demonstrates Long-Term Cost-Effectiveness of Routine Patellar Resurfacing: Reported by Healio Orthopedics, Oxford investigators established a 99 percent probability of cost-effectiveness and superior quality-adjusted life-years over 20 years for routine patellar resurfacing in 1,715 total knee replacements.
• Multicenter Machine Learning Analysis Identifies Component Offset Exceeding 10 mm as Primary Dislocation Risk in Reverse Shoulder Arthroplasty: Reported by Healio Orthopedics, a multicenter analysis across 15 academic institutions found that combined lateral offset exceeding 10 mm quadruples dislocation risk from 1 percent to 4 percent following reverse shoulder arthroplasty.
• OrthoPediatrics Obtains 510(k) Clearance for Pediatric Nailing Platform Femur: OrthoPediatrics Corp. received FDA 510(k) clearance (K261345) for its Pediatric Nailing Platform Femur, indicated for pediatric femur fracture fixation.
• Zimmer Biomet Obtains 510(k) Clearance for G7® Acetabular System: Zimmer Biomet secured FDA 510(k) clearance (K261453) for its G7® Acetabular System, indicated for total hip arthroplasty reconstruction.

DAILY ANNOUNCEMENTS BY CATEGORY

Corporate, M&A & Regulatory

Johnson & Johnson / Smith+Nephew: J&J and Smith+Nephew $34 Billion Orthopaedics Mega-Merger Talks Collapse Over CEO Appointment Dispute

• Summary: Johnson & Johnson and Smith+Nephew terminated discussions to combine their orthopaedics businesses into a 34 billion dollar company following disagreements regarding executive leadership and the chief executive officer appointment. The proposed transaction valued DePuy Synthes at up to 22 billion dollars and Smith+Nephew at roughly 12.6 billion dollars, with Smith+Nephew planning to fund a 10 billion dollar cash payment to J&J through debt. Following the collapse of negotiations, Johnson & Johnson leadership indicated that the healthcare corporation is leaning toward executing a standalone public spin-off for DePuy Synthes.
• Key Details:
  • Device/System Name: DePuy Synthes / Smith+Nephew Combined Orthopaedics Entity (Proposed)
  • Status: Merger Negotiations Terminated / Independent Spin-Off Planned
  • Clinical Significance: A combined Johnson & Johnson and Smith+Nephew orthopaedics entity would have created a 34 billion dollar market leader rivaling Stryker and Zimmer Biomet across joint reconstruction, trauma, and sports medicine; the collapse directs J&J toward a standalone public spin-off for DePuy Synthes, reshaping supplier dynamics, implant purchasing contracts, and hospital procurement channels.
• Original Source: Orthopedics This Week

Joint Reconstruction

University of Oxford: Twenty-Year Randomized Controlled Trial in The Lancet Demonstrates Long-Term Cost-Effectiveness of Routine Patellar Resurfacing in Total Knee Arthroplasty

• Summary: Long-term follow-up from the multicenter KAT randomized controlled trial published in The Lancet evaluated 1,715 patients with a mean age of 70 years undergoing primary total knee replacement between 1999 and 2003 assigned to patellar resurfacing (861 patients) or non-resurfacing (854 patients). At 20 years, resurfaced patients demonstrated a 0.76 point advantage on the Oxford Knee Score, lower readmission rates, fewer secondary operations, and significantly higher quality-adjusted life-years (7.29 QALYs versus 6.88 QALYs). Health economic modeling established a 99 percent probability that routine patellar resurfacing is cost-effective at thresholds exceeding 10,000 pounds per QALY gained across 34 centers and 116 surgeons.
• Key Details:
  • Device/System Name: Patellar Resurfacing Components in Total Knee Replacement (KAT Trial 20-Year Cohort)
  • Status: Twenty-Year Pragmatic Multicenter Randomized Controlled Trial Published (The Lancet)
  • Clinical Significance: Demonstrates a 99 percent probability of cost-effectiveness and superior quality-adjusted life-years over two decades for routine patellar resurfacing, providing high-level longitudinal evidence to resolve ongoing debate regarding native patella retention versus resurfacing in primary knee arthroplasty.
• Original Source: Healio Orthopedics

Clinical & Registry Evidence

Duke University / ASES: Multicenter Machine Learning Analysis of 6,621 Reverse Shoulder Arthroplasties Identifies Combined Component Offset Exceeding 10 mm as Primary Dislocation Risk Factor

• Summary: A multicenter machine learning analysis across 15 academic institutions and 24 ASES surgeons evaluated 6,621 reverse shoulder arthroplasties performed between January 2013 and June 2019 with minimum 3-month follow-up, identifying an overall dislocation rate of 2.1 percent. Machine learning modeling revealed that absence of subscapularis repair, male sex, and younger age increased instability risk, while primary osteoarthritis was protective. Crucially, combined lateral offset of the glenoid and humeral components exceeding 10 mm quadrupled postoperative dislocation from 1 percent to 4 percent, with retentive liners and spacers frequently indicating uncorrected soft-tissue laxity.
• Key Details:
  • Device/System Name: Multicenter Machine Learning Dislocation Risk Model for Reverse Total Shoulder Arthroplasty
  • Status: Multicenter Machine Learning Cohort Study Presented (International Congress on Shoulder and Elbow Surgery / ASES)
  • Clinical Significance: Identifies that high combined glenoid and humeral lateral offset exceeding 10 mm quadruples dislocation risk from 1 percent to 4 percent following reverse shoulder arthroplasty, demonstrating that biomechanical construct planning and subscapularis repair are crucial modifiable factors to minimize postoperative instability.
• Original Source: Healio Orthopedics

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES: ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2 to 4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.